股票 › PTGX
主角治疗 PTGX
美股市值排名 #1585
$132.04 −$3.22 (-2.38%)
休市 · Nov 7, 10:00 pm ET · 最新盘后价 $132.04 0.00%
开盘$135.26
昨收$135.26
当日区间$128.00 – $138.40
成交量972.9K
市值$8.54B
市盈率（TTM）27.9
股息率–
PTGX 相关新闻
匹配 Protagonist Therapeutics 或代码 PTGX 的头条新闻，按最新排序。
- Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating
- Protagonist Therapeutics(PTGX.US) Officer Sells US$18.24 Million in Common Stock
- Citi Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $182
- A Quick Look at Today's Ratings for Protagonist Therapeutics(PTGX.US), With a Forecast Between $149 to $182
- J.P. Morgan Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $149
- H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $170
- Goldman Sachs Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $186
- A Quick Look at Today's Ratings for Protagonist Therapeutics(PTGX.US), With a Forecast Between $153 to $175
- H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $170 正面
- Wedbush Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $173
- BMO Capital Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $178
- BMO Capital Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $178 正面
- J.P. Morgan Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $149 正面
- A Quick Look at Today's Ratings for Protagonist Therapeutics(PTGX.US), With a Forecast Between $167 to $186
- Goldman Sachs Upgrades Protagonist Therapeutics(PTGX.US) to Buy Rating, Raises Target Price to $186 正面
暂无评论——快来第一个聊聊 PTGX。
登录后参与讨论。